NEW YORK, Aug. 22, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Foundation Medicine, Inc. (NASDAQ:FMI) who purchased shares between February 26, 2014 and November 3, 2015. The action, which was filed in the USDC for the District of Massachusetts, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose material information regarding: (1) the reimbursement process and likelihood of coverage for Foundation’s tumor tests by Medicare; and (2) the Company’s financial guidance. As a result of these false statements, Foundation common stock traded at artificially inflated prices during the Class Period.
On July 29, 2015, the Company disclosed that it was not making the strides obtaining coverage it had claimed to have been making during the Class Period, and that Foundation would receive no Medicare payments in 2015 for its tumor profiling tests due to a delay in receiving a local coverage determination from its regional Medicare Administrative Contractor. As a result of the delay, the Company slashed its 2015 financial guidance, which, unbeknownst to investors, was based on an assumption that Medicare approval was going to be obtained in 2015. Then, on November 3, 2015, the Company disclosed a further revision to the already reduced number of clinical tests it expected to report for 2015.
Shareholders have until September 26, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sbm/foundation-medicine-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com


Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
OpenAI Addresses Security Vulnerability in macOS App Certification Process
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 



